BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21239962)

  • 21. Enhanced suppression of the xenogeneic T-cell response in vitro by xenoantigen stimulated and expanded regulatory T cells.
    Jin X; Wang Y; Hawthorne WJ; Hu M; Yi S; O'Connell P
    Transplantation; 2014 Jan; 97(1):30-8. PubMed ID: 24092378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of CD39+, LAG3+, and CTLA4+ Regulatory T Cells in Two Different Immunosuppressive Protocols in Renal Allograft Recipients (Sirolimus vs Mycophenolate mofetil): A Cohort Report.
    Mollaei-Kandelous Y; Ahmadpoor P; Nafar M; Khatami MR; Farashi Bonab S; Tajik N; Shekarabi M; Amirzargar A
    Iran J Immunol; 2022 Sep; 19(3):219-231. PubMed ID: 36190377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose of tacrolimus favors the induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation.
    Wang Z; Shi B; Jin H; Xiao L; Chen Y; Qian Y
    Int Immunopharmacol; 2009 May; 9(5):564-9. PubMed ID: 19557878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cell density and HLA-DR incompatibility on T-cell proliferation and forkhead box P3 expression in human mixed lymphocyte reaction.
    Song EY; Han S; Yang B; Morris GP; Bui JD
    Transplant Proc; 2015 Apr; 47(3):763-9. PubMed ID: 25891727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The protein kinase C inhibitor sotrastaurin allows regulatory T cell function.
    de Weerd A; Kho M; Kraaijeveld R; Zuiderwijk J; Weimar W; Baan C
    Clin Exp Immunol; 2014 Feb; 175(2):296-304. PubMed ID: 24131367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function.
    Miroux C; Morales O; Ghazal K; Othman SB; de Launoit Y; Pancré V; Conti F; Delhem N
    Transplantation; 2012 Jul; 94(2):123-31. PubMed ID: 22743548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
    Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An assay for the determination of sirolimus levels in the lymphocyte of transplant patients.
    Masri M; Rizk S; Barbari A; Stephan A; Kamel G; Rost M
    Transplant Proc; 2007 May; 39(4):1204-6. PubMed ID: 17524933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF.
    Gallon L; Perico N; Dimitrov BD; Winoto J; Remuzzi G; Leventhal J; Gaspari F; Kaufman D
    Am J Transplant; 2006 Jul; 6(7):1617-23. PubMed ID: 16827862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ; Ji Q
    Transplant Proc; 2013; 45(1):153-6. PubMed ID: 23375290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling.
    Hu H; Dong Y; Feng P; Fechner J; Hamawy M; Knechtle SJ
    Transplantation; 2003 Apr; 75(7):1075-7. PubMed ID: 12698107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulatory effect of rapamycin and tacrolimus on monocyte-derived dendritic cells phenotype and function.
    Dahlqvist G; Renaud S; Barjon C; Lefebvre A; Aoudjehane L; Horsmans Y; Delhem N; Conti F
    Immunobiology; 2021 Jan; 226(1):152031. PubMed ID: 33278711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.
    Anil Kumar MS; Heifets M; Fyfe B; Saaed MI; Moritz MJ; Parikh MH; Kumar A
    Transplantation; 2005 Sep; 80(6):807-14. PubMed ID: 16210969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.
    Levitsky J; Miller J; Wang E; Rosen A; Flaa C; Abecassis M; Mathew J; Tambur A
    Hum Immunol; 2009 Mar; 70(3):146-50. PubMed ID: 19141306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.
    Singh K; Kozyr N; Stempora L; Kirk AD; Larsen CP; Blazar BR; Kean LS
    Am J Transplant; 2012 Jun; 12(6):1441-57. PubMed ID: 22300641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
    Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
    Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.